

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

NCT07177300

Status	RECRUITING
Phase	Phase 4
Sponsor	Children's Hospital Medical Center, Cincinnati
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (3)

- Diagnosis of sickle cell anemia (HbSS) or sickle- α thalassemia (HbS α)
- Age 6 months at the time of enrollment
- Clinical decision by patient, family, and healthcare provider to initiate hydroxyurea therapy

Exclusion (2)

- Current treatment with regularly scheduled blood transfusions
- Sickle-hemoglobin C disease (HbSC), sickle- β thalassemia (HbS β)

Locations (1 total)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States